Taysha Gene Therapies develops gene therapies for severe brain disorders, with its lead candidate aimed at Rett syndrome. It last closed at $3.72 on Nov 20, down 1.33% on the day. The next earnings report for TSHA is expected around Thu, Mar 18, 2027. For the quarter ended Sep 2026, TSHA reported EPS of -$0.10 on revenue of $0. Over its last 8 reports the stock moved an average of 3.9% the session after earnings. Over the last 12 months TSHA insiders bought $0 of stock on the open market and sold $6.7M, according to SEC Form 4 filings.
AI Auto Pilots
Is TSHA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold TSHA.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on TSHAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
TSHA · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 11% below its 20 day and 17% below its 50 day average. It is 42% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot at $3.71, and the nearest resistance the Pivot R1 at $3.81.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 7.3%/day
Key levels
$7.3052 week high+96.2%
$5.28200 day average+41.9%
$5.15100 day average+38.4%
$4.3550 day average+16.9%
$4.26Swing high (Oct 21)+14.5%
$4.1220 day average+10.8%
$3.81Pivot R1+2.4%
$3.72Last close
$3.71Pivot−0.3%
$3.62Pivot S1−2.7%
$3.4652 week low−7.0%
$3.46Swing low (Oct 14)−7.0%
Indicators
RSI (14)
34.73
Weak, oversold below 30
Neutral
MACD
-0.13
Below its signal line
Bearish
Stochastic
9.0
Near the bottom of its range
Oversold
ADX (14)
14.7
No clear trend
Williams %R
-87.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-239.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−14.1%
Change over 10 sessions
Bearish
ATR (14)
$0.27
Typical daily range, 7.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 18.0%/day
Key levels
$7.3052 week high+96.2%
$5.28200 day average+41.9%
$5.15100 day average+38.4%
$4.3550 day average+16.9%
$4.26Swing high (Oct 21)+14.5%
$4.1220 day average+10.8%
$3.81Pivot R1+2.4%
$3.72Last close
$3.71Pivot−0.3%
$3.62Pivot S1−2.7%
$3.4652 week low−7.0%
$3.46Swing low (Oct 14)−7.0%
Indicators
RSI (14)
36.23
Weak, oversold below 30
Neutral
MACD
-0.42
Below its signal line
Bearish
Stochastic
18.3
Near the bottom of its range
Oversold
ADX (14)
24.0
Weak trend
Williams %R
-91.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-110.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−25.9%
Change over 10 sessions
Bearish
ATR (14)
$0.67
Typical daily range, 18.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for TSHA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how TSHA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow TSHA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for TSHAHow many large options trades hit TSHA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in TSHA in the last 90 days.
From SEC Form 4 filings by TSHA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TSHA is in one of them and how their past TSHA trades turned out.
Taysha Gene Therapies is a biotechnology company based in Dallas, Texas, that develops gene therapies for severe diseases of the central nervous system. Its lead candidate, TSHA-102, is being tested for Rett syndrome, a genetic disorder that mainly affects girls and causes loss of speech, hand use and motor skills. The treatment is still in clinical trials, and its intended users are patients with Rett syndrome and their caregivers.